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Original Article
Efficacy and Safety of Non-Vitamin
K Antagonist Oral Anticoagulants
in Asians With Nonvalvular Atrial
Fibrillation: A Network Meta-Analysis
Qinmei Xiong, MD, PhD1, Cen Wang, MD1, Hualong Liu, MD1,
Zhaochong Tan, MD1, Chen Chen, MD1, Juxiang Li, MD1,
Gregory Y. H. Lip, MD2,3, and Kui Hong, MD, PhD1,4
Abstract
There are few head-to-head trials directly comparing non-vitamin K antagonist oral anticoagulants (NOACs) against one other.
A network meta-analysis (NMA) was performed to examine the indirect comparisons among NOACs in Asians with nonvalvular
atrial fibrillation (NVAF). STATA 15.0 and ADDIS 1.16.8 softwares were used to perform the statistical analysis. Odds ratios with
95% credible intervals were applied to evaluate the end points. The probabilities of treatment rank were used to understand
which interventions are more effective and safe, and the total rank probability was 1. In our NMA, the rank probabilities of
apixaban in the case of stroke or systemic embolism, death from any cause, major bleeding, and intracranial hemorrhage (ICH)
were 0.47, 0.49, 0.42, and 0.51, respectively. For cases of myocardial infarction, the rank probabilities of rivaroxaban were 0.40.
This NMA indirectly compares the main efficacy and safety end points among NOACs in Asians with NVAF, and the rank
probability analysis showed that apixaban likely performs best in cases of stroke or systemic embolism, death from any cause, and
ICH; rivaroxaban may have the best performance for myocardial infarction.
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Introduction
Patients with nonvalvular atrial fibrillation (NVAF) are at
increased risk of stroke and death.1,2 Warfarin, one of the
Vitamin K antagonists, is an effective therapy in preventing
stroke or systemic embolism for patients with NVAF.3-5 How-
ever, there are some limitations for underuse of warfarin in
clinical practice, such as a narrow therapeutic range and mul-
tiple interactions with food and drugs, requiring frequent
laboratory coagulation monitoring and dose adjustments.
Thus, several non-vitamin K antagonist oral anticoagulants
(NOACs) have been developed and validated in large rando-
mized trials, compared to warfarin.6-9 All of the 4 NOACs
have been confirmed to be superior or at least noninferior to
warfarin in preventing stroke or systemic embolism, with
lower rates of bleeding and mortality.6-9
Many studies have shown that warfarin is more underused in
East Asia versus other regions of the world.10 The effect of
NOACs in Asian NVAF populations has been recently evalu-
ated, including a number of real-world studies.11-19 In rando-
mized trials, the NOACs appear to have greater efficacy and
better safety in Asians compared to non-Asians.20 The lower
body weight and body mass index (BMI) in Chinese
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populations might be associated with the efficacy and safety of
NOACs.21,22
Nevertheless, there are no head-to-head trials conducted to
directly compare these NOACs against each other. An indirect
comparison analysis on comparing the efficacy and safety of
edoxaban to other agents has been recently published23 but did
not focus on Asian patients. In Asia, clinicians and patients are
interested in identifying which of the NOACs performs better
among Asian patients with NVAF. We performed a systematic
review and network meta-analysis (NMA) to compare the effi-
cacy and safety of these 4 NOACs compared to each other,
based on Asian data.
Methods
Inclusion and Exclusion Criteria
The following inclusion criteria were applied for selecting
studies: (1) Types of studies: clinical studies focusing on the
efficacy and safety of NOACs among Asian NVAF patients;
(2) Participants: anticoagulated Asians with NVAF; and (3)
Outcomes: (i) efficacy end points: stroke or systemic embo-
lism, myocardial infarction, and death from any cause; (ii)
safety end points: major bleeding defined according to the
2005 International Society on Thrombosis and Hemostasis cri-
teria24 and clinically relevant nonmajor bleeding. Studies with
insufficient data (not describe the data of NOACs, respec-
tively), those not published in English, and certain publication
types (eg, conference, abstracts, letters, comments, case
reports, and reviews) were excluded from this NMA.
Literature Search
A comprehensive literature search of the PubMed, Elsevier,
and Cochrane Library electronic databases was conducted by
2 independent reviewers (Qinmei Xiong and Cen Wang). The
included studies were published from December 2010 to June
2019. Search terms included “atrial fibrillation,” “NOACs,”
“dabigatran,” “apixaban,” “rivaroxaban,” and “edoxaban.”
No research meeting the inclusion criteria was found in the
manual search.
Data Extraction and Quality Assessment of Individual
Studies
Data extraction was performed independently by 2 reviewers
based on the inclusion and exclusion criteria. Initial screening
was conducted by reading titles and abstracts of all studies. Full
texts of selected research articles were then reviewed to con-
firm if those studies met the inclusion criteria. Additionally,
disagreements were resolved through discussion or consulta-
tion with a third reviewer (Kui Hong).
Network Meta-Analysis and Statistical Analysis
Network meta-analysis was conducted to pool the results of
direct and indirect comparisons using a Bayesian approach. All
data were analyzed using STATA 15.0 and ADDIS (Aggregate
Data Drug Information System) 1.16.8 software (Drug Infor-
mation Systems, Groningen, the Netherlands). We first per-
formed a pairwise meta-analysis to directly evaluate the
treatment effect of NOACs. The odds ratio (OR) with a 95%
confidence interval (CI) was applied to evaluate the end points.
For the NMA, ORs with 95% credible intervals (CrIs) were
used. Moreover, a consistency model based on the Markov
chain Monte Carlo simulation method was applied by using
50 000 simulation iterations for each 4 chains with a burn-in
period of the first 20 000 iterations. Node-splitting analysis and
inconsistency standard deviation (ISD) were then performed to
evaluate the consistency of the data. When the P value of the
node-splitting analysis was >.05 and the 95% CI of the ISD
contained 1, the consistency model was selected.25 Conver-
gence was evaluated using potential scale reduction factor
(PSRF) and the Brooks-Gelman-Rubin method, and a value
of *1 represented good convergence. Value of P < .05 was
regarded as a statistically significant result. We could also use
the probabilities of treatment rankings to understand which
interventions are more effective and safe; the total rank prob-
ability was 1. According to our pooled result, Rank 1 was the
worst and Rank N was the best.
Results
Flow Diagram of Literature Search
Using the above-mentioned search strategies, we found a total
of 1111 studies (743 in PubMed, 262 in Elsevier, 106 in
Cochrane Library). We excluded 785 studies by reading the
titles and abstracts. When we screened the full texts, 291 stud-
ies were eliminated because these studies did not relate to
NOACs, Asian populations, and atrial fibrillation. Finally,
18 studies were included. The other studies were excluded for
the following reasons: (1) certain publication types with no
data (n ¼ 7); (2) duplicate data without follow-up (n ¼ 4);
(3) studies not published in English (n ¼ 3); and (4) studies
not describing NOACs (apixaban, dabigatran, rivaroxaban, and
edoxaban; n ¼ 3; Figure 1).
Characteristics of the Included Studies and Patients
All 18 included studies were conducted in China,12,13,15,18,26-28
Singapore,12,15,19 Korea,12-15,17-19,29 Japan,12,13,15,30,31 India12,
Malaysia,11,12,15,16,32 the Philippines,12,15 Turkey,33 Israel,34 or
Thailand.12 A total of 71 227 anticoagulated patients with
NVAF were studied. The oral anticoagulants were warfarin,
apixaban, dabigatran, edoxaban, and rivaroxaban (Table 1).
Pairwise Meta-Analysis
The risk of stroke or systemic embolism was decreased by 60%
and 55% for patients who took dabigatran and rivaroxaban,
respectively, when compared to those who took warfarin (dabi-
gatran vs warfarin [OR ¼ 0.4; 95% CI: 0.26-0.6] and rivarox-
aban vs warfarin [OR ¼ 0.45; 95% CI: 0.28-0.72]). For death
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from any cause risk, the risk was decreased by 63% and 66%
for patients who took rivaroxaban and dabigatran when com-
pared to those who took warfarin (rivaroxaban vs warfarin:
OR ¼ 0.37; 95% CI: 0.21-0.67; dabigatran vs warfarin:
OR ¼ 0.34, 95% CI: 0.13-0.91). When compared to those who
took warfarin, intracranial hemorrhage (ICH) was decreased
by 81%, 67%, and 76% among patients who took apixaban,
dabigatran, or rivaroxaban, respectively (apixaban vs warfarin:
OR ¼ 0.19, 95% CI: 0.05-0.72; dabigatran vs warfarin: OR ¼
0.33, 95% CI: 0.2-0.54; rivaroxaban vs warfarin: OR ¼ 0.24,
95% CI: 0.18-0.33). No significant difference was found for
myocardial infarction and major bleeding (Figure 2).
Network Meta-Analysis
In our NMA, the indirect comparisons of the NOACs were
based on the published direct comparisons with the NOACs
against warfarin. The data for this section were consistent with
the pairwise meta-analysis. In node-splitting analysis, all of the
P values were over .05, with the 95% CI of the ISD containing
1 and all of the PSRFs ranging from 1.00 to 1.01. This indicated
that all included studies had good consistence, and the model
obtained good convergence. Therefore, the consistency model
was selected.
The indirect comparisons of all of the end points for the oral
anticoagulants are shown in (Supplemental Table 1). There are
Figure 1. Flow diagram of literature search.
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13 studies providing data on 15 direct comparisons between 4
different treatment nodes for major bleeding, 13 studies pro-
viding data on 20 direct comparisons between 4 different treat-
ment nodes for stroke or systemic embolism, 13 studies
providing data on 21 direct comparisons between 4 different
treatment nodes for intracranial bleeding, 9 studies providing
data on 14 direct comparisons between 4 different treatment
nodes for death from any cause, and 6 studies providing data on
6 direct comparisons between 4 different treatment nodes for
myocardial infarction (Figure 3). All the results of the NMA
were consistent with the pairwise meta-analysis, but there were
no significant differences among the NOACs in the 5 end
points (Supplemental Table 1).
Although no significant differences were shown for all of
the selected end points in the NMA, the rank probability of the
5 oral anticoagulants showed the degree of drug efficacy in
each end point, which may provide guidance for medical
decision-making in clinical practice. Apixaban likely has the
most effective drug for the prevention of stroke or systemic
embolism, death from any cause, major bleeding, and ICH,
with rank probabilities of 0.47, 0.49, 0.42, and 0.51, respec-
tively. For cases of myocardial infarction, rivaroxaban may be
considered as the best drug, with ranking probabilities of 0.40
(Supplemental Figure 1).
Discussion
Our pairwise meta-analysis has demonstrated that dabigatran
and rivaroxaban performed better than warfarin in cases of
stroke or systemic embolism and death from any cause; apix-
aban, dabigatran, and rivaroxaban had a lower risk of ICH
compared to warfarin. In our NMA, the ORs with 95% CrIs
demonstrated no significant differences among the NOACs.
Rank probability analysis showed that apixaban may have the
highest efficacy for stroke or systemic embolism, death from
any cause, major bleeding, and ICH; rivaroxaban may have the
best performance for myocardial infarction. As far as we are
aware, this is the first NMA comparing NOACs that is focused
on Asian patients with NVAF.
The pairwise meta-analysis in Asians was generally consis-
tent with previous studies. In the Randomized Evaluation of
Long-Term Anticoagulation Therapy trial, for example, dabi-
gatran was superior to warfarin for stroke or systemic embo-
lism, myocardial infarction, major bleeding, and intracranial
bleeding.7 In the Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K Antagonism for Pre-
vention of Stroke and Embolism Trial in Atrial Fibrillation
trial, rivaroxaban had a lower risk of ICH when compared to
warfarin.9 In the Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation trial, apixaban
was superior to warfarin for stroke or systemic embolism, death
from any cause, major bleeding, and intracranial bleeding.6 In
the Effective Anticoagulation with Factor Xa Next Generation
in Atrial Fibrillation Thrombolysis in Myocardial Infarction 48
trial, edoxaban had a lower risk of death from any cause, major
bleeding, and ICH when compared to warfarin.8 Unfortunately,
these 4 studies did not directly evaluate the differences in effi-
cacy and safety comparing those NOACs to one another.
Table 1. Summary of Patients’ Characteristics in 18 Included Studies.
Study Country
Follow-Up,
months
Study
Arms N Drug End Points
Chung et al (2011)19 Korea, Singapore 12 2 235 E/V Major bleeding
Hori et al (2013)12 China, Japan, Korea, India,
Malaysia, Philippines,
Singapore, Thailand
24 2 2782 D/V Stroke/SE; MI; Death; Major bleeding; ICH
Wong et al (2014)18 China, Korea 22 2 932 R/V Stroke/SE; MI; Death; Major bleeding; ICH
Goto et al (2014)15 China, Japan, Korea, Philippines,
Malaysia, Singapore
20 2 1993 A/V Stroke/SE; MI; Death; Major bleeding; ICH
Yap et al (2016)11 Malaysia 20 2 1000 D/V Stroke/SE; Major bleeding; ICH
Yamashita et al (2016)13 Japan, China, Korea 24 2 1943 E/V Stroke/SE; MI; Death; Major bleeding; ICH
Cha et al (2017)14 Korea 24 4 34 833 A/D/R/V Stroke/SE; Death; ICH
Lee et al (2017)17 Korea 24 2 1098 D/V Stroke/SE; MI; Death; Major bleeding; ICH
Beshir et al (2018)16 Malaysia 12 3 1017 D/R/V Major bleeding
Jeong et al (2019)29 South Korea 12 2 1608 R/V Stroke/SE; MI; Death; Major bleeding; ICH
Mao et al (2014)28 China 18 2 353 R/V Stroke/SE; major bleeding; ICH
Yamashita et al (2012)31 Japan 12 2 519 E/V Major bleeding
Yap et al (2017)32 Malaysia 93 2 200 D/V Stroke/SE; ICH
Naganuma et al (2017)30 Japan 10 2 362 D/V Stroke/SE; Major bleeding
Li et al (2017)26 China 22 3 2099 D/R/V Stroke/SE; ICH
Ho et al (2015)27 China 36 2 1821 D/V Stroke/SE; Death; ICH
Yiginer et al (2016)33 Turkey 17 2 183 D/R Death; Major bleeding; ICH
Ellis et al (2016)34 Israel 8 3 18 249 D/R/V ICH
Abbreviations: SE, systemic embolism; MI, myocardial infarction; ICH, intracranial hemorrhage; V, vitamin-K antagonists (Warfarin); A, apixaban; D, dabigatran;
R, rivaroxaban.
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Cha et al14 reported that rivaroxaban had a 1.94-fold ele-
vated risk of stroke or systemic embolism when compared to
apixaban (rivaroxaban vs apixaban: OR ¼ 1.94; 95% CI: 1.01-
3.71). In the death from any cause, dabigatran and rivaroxaban
had a 2.22- and 3.83-fold elevated risk when compared to
apixaban, respectively (dabigatran vs apixaban: OR ¼ 2.22,
95% CI: 1.20-4.10; rivaroxaban vs apixaban: OR ¼ 3.83,
95% CI: 2.16-6.79), and rivaroxaban has a 1.72-fold elevated
risk when compared to dabigatran (rivaroxaban vs dabigatran:
OR ¼ 1.72, 95% CI: 1.24-2.40).
Body weight and BMI in Asians have been found to be
lower than in white populations in many studies.21,22 Low body
weight (60 kg) is an important covariate for bleeding, and
Cha et al reported that being underweight increases the risk of
major bleeding and all-cause death when compared to being
normal weight or overweight.14
Indeed, Asians may have a propensity for bleeding events
when taking warfarin.12 For example, a previous study showed
that Asian patients with AF treated with warfarin had a 4-fold
higher hazard ratio (HR) for ICH when compared to whites.22
In a recent meta-analysis, the incidence of ICH was approxi-
mately 2-fold higher in Asians compared to whites.35 Addition-
ally, the salt sensitivity of different ethnic groups may be
related to ICHs.36 Because more Asian patients with AF had
ICH than did non-Asians, the developing countries appear to
have 80% of the global burden of ICH.37
Several studies have demonstrated that patients with AF
used NOACs to reduce the risk of bleeding.38,39 In our pairwise
meta-analysis, apixaban, dabigatran, and rivaroxaban had a
lower risk than warfarin for ICH. In our NMA, the ORs with
95% CrIs demonstrated no significant differences among the
NOACs, but the rank probability analysis showed that apixaban
had the highest probability of performing the best among all
anticoagulants for ICH.
Limitations
As an indirect comparison analysis, the present NMA has some
inherent limitations. We found only 5 head-to-head studies on
NOACs, and the 5 studies were conducted in China,26
Figure 2. Pairwise meta-analysis results for 5 oral anticoagulants in 5 end points.
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Malaysia,16 Israel,34 and Korea.14 More direct comparisons
should be performed as the findings of indirect comparisons
can only be considered as guidance for clinical practice. More-
over, heterogeneity for clinical, methodological, and statistical
limitations always exists.
Conclusion
In our NMA, to indirectly compare the main efficacy and safety
end points among NOACs in Asians with NVAF, there were no
significant differences among the NOACs for efficacy, but rank
probability analysis showed that apixaban probably performs
best in stroke or systemic embolism, death from any cause,
major bleeding, and ICH. For cases of myocardial infarction,
rivaroxaban may be considered as the best drug.
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